158 related articles for article (PubMed ID: 17352798)
1. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
[TBL] [Abstract][Full Text] [Related]
3. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
[TBL] [Abstract][Full Text] [Related]
6. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
8. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
10. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
11. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
[TBL] [Abstract][Full Text] [Related]
13. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
[TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
[TBL] [Abstract][Full Text] [Related]
17. Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?
de Requena DG; Núñez M; Gallego O; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2002; 3(6):463-7. PubMed ID: 12501129
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
[TBL] [Abstract][Full Text] [Related]
19. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
